Oncologists expect Avastin Rxs to more than double: survey
A recent survey of oncologists indicates market share for Genentech's Avastin could more than double as a first-line and second-line breast cancer therapy following last month's approval to treat the disease.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.